SecBot SecBot
PRESS-RELEASE ·Filed Nov 4, 2026

BCAX

Bicara Therapeutics Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed12d 14h ago WireGlobeNewswire
Press release · Activist
Actionable Insight • Neutral

This is a routine inducement grant for a new hire with no immediate read-through for the stock. Monitor upcoming clinical data readouts for ficerafusp alfa in head and neck squamous cell carcinoma.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$8.89
T+0 close · Nov 4, 2026 · via day close
Latest settled
+18.45%
T+5 · $10.53
Vs SPY
+19.36%
α at T+5
Next horizon
T+20
in 16d
  1. T+0 · Nov 4 $8.89entry
  2. T+1 · 12d ago −7.87%α −3.46% · $8.19
  3. T+5 · 6d ago +18.45%α +19.36% · $10.53
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Bicara Therapeutics granted a new employee a non-qualified stock option to purchase 50,000 shares at $7.93 per share as a material inducement to employment under its 2026 Inducement Plan. The award is routine and immaterial relative to the company's market cap of $604M.

Key Facts

  • One new employee received a non-qualified stock option to purchase 50,000 shares at $7.93 per share.
  • Exercise price equals the November 2, 2026 closing price of $7.93.
  • Options vest over four years: 25% on first anniversary, then quarterly over three years.
  • Grant was approved by the compensation committee as a material inducement under Nasdaq Listing Rule 5635(c)(4).

Financial Impact

50,000 shares at $7.93 exercise price; maximum potential dilution of ~0.07% of outstanding shares based on market cap of $604M and stock price of $7.93.

dilution

Risk Factors

  • No material risk from this grant; standard equity compensation for a new employee.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3395298

Track record

26 reports on BCAX

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +5.65% at T+20 after the Apr 15, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $9.98 Now $9.75 −2.30% settles Dec 8
  2. Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
  3. Nov 4, 202612d ago Press Release Neutral 2/10 Viewing Entry $8.89 Now $9.75 +9.67% settles Dec 3
  4. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $16.42 to $8.89 Now $9.75 −40.62% ▼ −45.86% −44.52% vs SPY
  5. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $17.29 to $9.13 Now $9.75 −43.61% ▼ −47.19% −44.73% vs SPY
  6. Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $22.78 to $18.35 Now $9.75 −57.20% ▼ −19.45% −18.89% vs SPY
  7. Aug 25, 202611w ago 8-K Neutral 2/10 Entry $24.73 to $19.78 Now $9.75 −60.57% ▼ −20.02% −20.24% vs SPY
  8. Aug 14, 202613w ago Press Release Neutral 2/10 Entry $24.28 to $23.20 Now $9.75 −59.84% ▼ −4.45% −2.46% vs SPY
  9. Aug 12, 202613w ago Insider Cluster Neutral Not scored Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
  10. Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (10h 8m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026